Over-production of pro-survival Bcl-2 proteins is not only a molecular mechanism behind many cancers but confers resistance to treatment by preventing their natural programmed death.
We will explore the molecular structures of the Bcl-2 proteins and anticipate designing drugs that directly inhibit pro-survival Bcl-2 proteins letting loose the natural cell death processes to kill cancer cells selectively.
Dr Mark Hinds, Dr Catherine Day
Cancer Council Research Grant
Walter & Eliza Hall Institute of Medical Research
$100,000 per annum